{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&min-answer.questionFirstAnswered.=2024-05-13T09%3A25%3A36.92Z", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&min-answer.questionFirstAnswered.=2024-05-13T09%3A25%3A36.92Z", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&min-answer.questionFirstAnswered.=2024-05-13T09%3A25%3A36.92Z&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&_page=0&min-answer.questionFirstAnswered.=2024-05-13T09%3A25%3A36.92Z", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&min-answer.questionFirstAnswered.=2024-05-13T09%3A25%3A36.92Z", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&min-answer.questionFirstAnswered.=2024-05-13T09%3A25%3A36.92Z", "items" : [{"_about" : "http://data.parliament.uk/resources/1724751", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1724751/answer", "answerText" : {"_value" : "
The wellbeing and safety of women accessing abortion services, including early medical abortion at home, is our first and foremost priority. Before prescribing abortion medicine for use at home, either an in-person or a virtual consultation is held with the woman concerned. If any health issues are identified during a virtual consultation which could make home use of early medical abortion medicine potentially unsuitable, the woman will be asked to attend an in-person appointment for further assessment.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/347", "label" : {"_value" : "Biography information for Baroness Merron"} } , "answeringMemberPrinted" : {"_value" : "Baroness Merron"} , "dateOfAnswer" : {"_value" : "2024-08-06", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-08-06T08:36:47.227Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-07-30", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Abortion: Drugs"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask His Majesty's Government what steps they are taking to ensure that any risks to a woman's health are accurately assessed before she may be sent abortion pills to be taken at home.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4184", "label" : {"_value" : "Biography information for Baroness Eaton"} } , "tablingMemberPrinted" : [{"_value" : "Baroness Eaton"} ], "uin" : "HL494"} , {"_about" : "http://data.parliament.uk/resources/1724759", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1724759/answer", "answerText" : {"_value" : "
Abortion providers are required to have effective arrangements in place to safeguard children and vulnerable adults, in compliance with the Department\u2019s required standard operating procedures for the approval of independent sector places for termination of pregnancy in England. Providers must ensure that all staff are trained in recognising the signs of potential abuse and coercion in adult women, and how to respond.<\/p>
In addition, the Royal College of Paediatrics and Child Health (RCPCH) has published national safeguarding guidance for under 18-year-olds accessing early medical abortion services, which will ensure that robust safeguarding processes are embedded across all abortion services. We expect all providers to have due regard to the RCPCH safeguarding guidance.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/347", "label" : {"_value" : "Biography information for Baroness Merron"} } , "answeringMemberPrinted" : {"_value" : "Baroness Merron"} , "dateOfAnswer" : {"_value" : "2024-08-02", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-08-02T13:43:39.483Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-07-30", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Abortion: Drugs"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask His Majesty's Government what steps they are taking to ensure that abortion providers verify that a woman is not being coerced into an abortion before she is sent abortion pills to be taken at home.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3902", "label" : {"_value" : "Biography information for Baroness O'Loan"} } , "tablingMemberPrinted" : [{"_value" : "Baroness O'Loan"} ], "uin" : "HL522"} , {"_about" : "http://data.parliament.uk/resources/1724771", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1724771/answer", "answerText" : {"_value" : "
The Government is currently considering the work done to date on introducing regulatory oversight of the non-surgical cosmetics sector in England, and will set out its views at the earliest opportunity.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/347", "label" : {"_value" : "Biography information for Baroness Merron"} } , "answeringMemberPrinted" : {"_value" : "Baroness Merron"} , "dateOfAnswer" : {"_value" : "2024-08-06", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-08-06T08:27:42.67Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-07-30", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Non-surgical Cosmetic Procedures: Licensing"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask His Majesty's Government, further to the Written Answer by Lord Markham on 5 April (HL3640), when they intend to publish feedback to the licensing of non-surgical cosmetic procedures consultation, which ran from 2 September to 28 October 2023.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4308", "label" : {"_value" : "Biography information for The Lord Bishop of St Albans"} } , "tablingMemberPrinted" : [{"_value" : "The Lord Bishop of St Albans"} ], "uin" : "HL534"} , {"_about" : "http://data.parliament.uk/resources/1723943", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1723943/answer", "answerText" : {"_value" : "
The following table shows the total number of items issued for trazodone from 2014 to 2023, and from January to May 2024:<\/p>
Year<\/p><\/td> | Total number of items<\/p><\/td><\/tr> | ||||||||||||||||||||||||
2014<\/p><\/td> | 1,050,069<\/p><\/td><\/tr> | ||||||||||||||||||||||||
2015<\/p><\/td> | 1,083,974<\/p><\/td><\/tr> | ||||||||||||||||||||||||
2016<\/p><\/td> | 1,112,437<\/p><\/td><\/tr> | ||||||||||||||||||||||||
2017<\/p><\/td> | 1,133,363<\/p><\/td><\/tr> | ||||||||||||||||||||||||
2018<\/p><\/td> | 1,157,717<\/p><\/td><\/tr> | ||||||||||||||||||||||||
2019<\/p><\/td> | 1,168,715<\/p><\/td><\/tr> | ||||||||||||||||||||||||
2020<\/p><\/td> | 1,191,060<\/p><\/td><\/tr> | ||||||||||||||||||||||||
2021<\/p><\/td> | 1,226,973<\/p><\/td><\/tr> | ||||||||||||||||||||||||
2022<\/p><\/td> | 1,238,983<\/p><\/td><\/tr> | ||||||||||||||||||||||||
2023<\/p><\/td> | 1,281,049<\/p><\/td><\/tr> | ||||||||||||||||||||||||
2024<\/p><\/td> | 553,866<\/p><\/td><\/tr><\/tbody><\/table> Source: data was provided by the NHS Business Service Authority, based on information within the Prescription Cost Analysis published statistics, using British National Formulary chemical substance trazodone hydrochloride. The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for ensuring medicines, medical devices, and blood components for transfusion meet applicable standards of safety, quality, and efficacy. The MHRA rigorously assesses the available data, including from the Yellow Card scheme, and where appropriate it seeks advice from its independent advisory committee, the Commission on Human Medicines, to inform on regulatory decisions, including the amending of product information.<\/p> The MHRA has received a total of 20 Yellow Card reports of sexual dysfunction related reactions, suspected to be associated with trazodone, between 1 January 2014 and 29 July 2024. This includes reactions grouped under the medical dictionary\u2019s (MedDRA) Higher Level Terms, which are more specific than sexual dysfunction and persistent sexual dysfunction, and include erection and ejaculation conditions and disorders, orgasmic disorders and disturbances, sexual arousal disorders, and others. The following table shows the number of spontaneous suspected Yellow Card reports of sexual dysfunction related reactions suspected to be associated with trazodone in the United Kingdom, received by the MHRA each year from 2014 to 2024:<\/p>
|